CagriSema news and clinical trials

Diabetes, obesity & metabolism published an erratum correcting a previous secondary, post hoc analysis of the REDEFINE 1 trial regarding the efficacy of CagriSema.

New meta-analysis in Frontiers in endocrinology: CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis.

Researchers published the design and baseline characteristics of the REDEFINE 3 trial, a study investigating the cardiovascular safety and efficacy of CagriSema. The trial randomized 7076 adults with cardiovascular disease between 1/2023 and 12/2024.

New paper in Diabetes, metabolic syndrome and obesity : targets and therapy: Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials.

Novo Nordisk A/S registered a phase 3 study with 210 participants to examine the safety and tolerability of switching from semaglutide to CagriSema in people with type 2 diabetes.

New review in Naunyn-Schmiedeberg's archives of pharmacology: Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.

New paper in Annals of medicine and surgery (2012): Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.

Novo Nordisk A/S completed a phase 2 trial (NCT06797869) with 142 participants to investigate the effects of CagriSema compared to a placebo in individuals with type 2 diabetes and painful diabetic peripheral neuropathy.

A post hoc analysis of the phase 3a REDEFINE 1 trial found that a higher proportion of participants achieved anthropometric targets with CagriSema compared to semaglutide, cagrilintide, or placebo. At week 68, 30.3% of CagriSema recipients met both BMI and waist-to-height ratio targets.

Novo Nordisk A/S completed a phase 3 study of 1023 participants to compare the efficacy of 1.0 mg/1.0 mg CagriSema versus 5 mg tirzepatide for blood sugar and body weight reduction in people with type 2 diabetes.

Novo Nordisk A/S withdrew a phase 2 clinical trial that was set to compare two versions of injectable CagriSema in people with type 2 diabetes. The study was stopped due to strategic reasons.

Novo Nordisk A/S withdrew a phase 3 study that was intended to compare two versions of CagriSema in people with excess body weight, citing strategic reasons.

New paper in Journal of diabetes science and technology: Ease of Use, Ease of Learning, and Convenience of the CagriSema Dual-Chamber Pen: Results From a Usability Study in Adults With Overweight, Obesity, or Type 2 Diabetes.

New randomized trial in Lancet (London, England): Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.

A phase 3 study of 2713 participants with type 2 diabetes and obesity investigated the efficacy of the fixed-dose combination CagriSema versus semaglutide or cagrilintide alone over 68 weeks.

New randomized trial in The lancet. Diabetes & endocrinology: Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase….

New review in Journal of diabetes and metabolic disorders: Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.

Novo Nordisk A/S registered a phase 3 clinical trial to compare the efficacy and safety of two doses of CagriSema versus semaglutide in 2500 participants with obesity or type 2 diabetes.

Novo Nordisk completed a phase 3 trial evaluating the efficacy and safety of CagriSema, a combination of cagrilintide and semaglutide, in 300 participants with obesity. The study assessed weight loss outcomes using weekly 1.0 mg/1.0 mg and 1.7 mg/1.7 mg doses.

Novo Nordisk registered a phase 1 trial for 100 participants to examine the effects of CagriSema, cagrilintide, and semaglutide on muscle health in individuals with excess body weight and slightly high blood sugar. The study evaluates skeletal muscle insulin sensitivity, composition, and function.

Novo Nordisk A/S completed a phase 3 trial with 1024 participants comparing the efficacy of CagriSema to tirzepatide in people with type 2 diabetes. The study measured blood sugar and body weight reduction.

A meta-analysis of 3 randomized controlled trials with 3,545 participants evaluated cagrisema and cagrilintide against semaglutide. Cagrisema produced significantly greater weight loss than semaglutide with a mean difference of -7.47% in body weight.

New meta-analysis in The American journal of cardiology: CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment.

Novo Nordisk completed a phase 1 trial involving 158 participants with type 2 diabetes to investigate how CagriSema, semaglutide, and cagrilintide regulate insulin effects. Participants received the study medicines in combination with metformin.

Novo Nordisk A/S registered a phase 2 trial to compare two versions of CagriSema in people with type 2 diabetes, but the study was withdrawn due to strategic reasons.

Novo Nordisk A/S registered a phase 3 study comparing two versions of CagriSema in people with excess body weight, but the trial was subsequently withdrawn due to strategic reasons.

Novo Nordisk completed a phase 3 trial comparing the weight loss efficacy of CagriSema against tirzepatide in 809 participants with obesity. The study administered 2.4 mg/2.4 mg of CagriSema or 15 mg of tirzepatide weekly via injection.

Novo Nordisk A/S completed a phase 3 trial (NCT06065540) involving 2734 participants to compare how well CagriSema lowers blood sugar and body weight in people with type 2 diabetes compared to semaglutide, cagrilintide, or placebo.

Novo Nordisk A/S completed a phase 3 study with 189 participants to assess the efficacy of CagriSema doses of 2.4 mg/2.4 mg and 1.0 mg/1.0 mg compared to placebo in people with type 2 diabetes.

Novo Nordisk A/S registered a phase 3 trial to assess the safety and efficacy of CagriSema compared to placebo in 80 children and adolescents with type 2 diabetes.

Novo Nordisk completed a phase 1 clinical trial of 164 participants investigating the effects of the combination treatment CagriSema on appetite and brain activity in adults with overweight or obesity.

Researchers conducting the 68-week REDEFINE 1 trial found that CagriSema 2.4 mg/2.4 mg significantly reduced blood pressure in adults with overweight or obesity compared to placebo. By week 68, systolic blood pressure dropped by 10.9 mm Hg for CagriSema users versus 2.8 mm Hg for placebo.

Novo Nordisk A/S registered a phase 3 trial with 460 participants to evaluate the efficacy, safety, and pharmacokinetics of Cagrilintide and CagriSema for weight management in children and adolescents with overweight or obesity.

Novo Nordisk A/S completed a phase 2 clinical trial (NCT06131372) involving 626 participants to assess if CagriSema reduces kidney damage in people with chronic kidney disease, type 2 diabetes, and obesity.